Leadership change Recent appointment of a new CEO, Hermes González-Bello, in January 2026 signals potential strategic shifts and renewed focus on growth initiatives. This presents an opening to engage on transformation programs, modernization of procurement, and alignment with new leadership priorities.

Growth potential Revenue range of 100M to 250M with 201-500 employees places Antylia as a mid‑size player ripe for expanded procurement of Molecular Diagnostic Reagents, specialty chemicals, lab equipment, and consumables to support scale-up in therapeutics, vaccines, and diagnostics programs.

Acquisition history Past divestitures and restructuring, including the 2021 asset sale to Avantor and prior leadership changes, indicate a company actively recalibrating its product portfolio and supplier relationships. There may be openness to strategic partnerships, divestments, or supplier consolidation opportunities.

Operational footprint New leadership and global operations experience among executives, plus a board presence, suggest emphasis on global sourcing, supply chain resilience, and international expansion. Target opportunities with end-to-end lab supply chains, compliance, and global distribution services.

Technology stack Adoption of cloud and marketing technologies (AWS, Planful, Pardot, Microsoft tools, KnowBe4) indicates a tech-enabled procurement and digital engagement approach. Leverage with targeted digital outreach, integrated purchasing portals, and data-driven account-based selling to modernize laboratory supply procurement.